Chembio Diagnostics Stock Is Trading Higher On FDA Emergency Use Nod For Its Partner's LumiraDX COVID-19 Antibody Test

  • The FDA has granted emergency use authorization to Chembio Diagnostics Inc's CEMI partner LumiraDx's COVID-19 antibody test.
  • LumiraDx and Chembio had announced a partnership on March 12, 2020 to develop point of care COVID-19 antibody test.
  • The nod comes for LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies in whole human blood, plasma, or serum for indication of recent or prior infection.
  • Recently, the Company received a $28 million order to supply DPP SARS-CoV-2 Antigen tests for delivery during 2021 in Brazil. 
  • Price Action: CEMI shares are up 15.1% at $3.39 during the market session on the last check Tuesday.
  • Related content: Benzinga's Full FDA Calendar.
  • Editor's note: The item has been updated to include the partnership details of Chembio and LumiraDx in the second bullet
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Long IdeasNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsEmergency Unemployment Compensation
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!